Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794748 | 0.86 | CA2 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL6492260 | 0.86 | CA2 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL7186459 | 0.84 | GPR84 (0.57) | GPR84FFAR1GRIK1SLC1A2SLC1A1 | |
| SCHEMBL14110749 | 0.84 | TDP1 (0.60) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5031485 | 0.84 | TDP1 (0.60) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL16794740 | 0.82 | GPR84 (0.61) | GPR84FFAR1GRIK1SLC1A2SLC1A1 | |
| SCHEMBL4282439 | 0.82 | GPR84 (0.61) | GPR84FFAR1GRIK1SLC1A2SLC1A1 | |
| SCHEMBL12920238 | 0.82 | GPR84 (0.61) | GPR84FFAR1GRIK1SLC1A2SLC1A1 | |
| SCHEMBL39649 | 0.82 | TDP1 (0.52) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL28212336 | 0.81 | TDP1 (0.57) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10340150-B2 | Ni:NiGe:Ge selective etch formulations and method of using same | ENTEGRIS, INC. (US) | 2019-07-02 | — | — | US | claimed |
| US-20160314990-A1 | NI:NIGE:GE SELECTIVE ETCH FORMULATIONS AND METHOD OF USING SAME | ENTEGRIS, INC. (US) | 2016-10-27 | — | — | US | claimed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| CN-118624704-A | Accurate control and ionization device for liquid drops for single-cell mass spectrometry and application of accurate control and ionization device | 中国检验检疫科学研究院 | 2024-09-10 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3080285-B1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-10340150-B2 | Ni:NiGe:Ge selective etch formulations and method of using same | ENTEGRIS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-9951356-B2 | Processes to prepare elongated 2-ketoacids and C6-C10 compounds therefrom via genetic modifications to microbial metabolic pathways | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160355850-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW AGROSCIENCES LLC | 2016-12-08 | — | — | US | disclosed |
| US-20160314990-A1 | NI:NIGE:GE SELECTIVE ETCH FORMULATIONS AND METHOD OF USING SAME | ENTEGRIS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3080285-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | Dow Global Technologies LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9320798-B2 | Lipid delivery formulations | DICERNA PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2015089127-A1 | PROCESSES TO PREPARE ELONGATED 2-KETOACIDS AND C6-C10 COMPOUNDS THEREFROM VIA GENETIC MODIFICATIONS TO MICROBIAL METABOLIC PATHWAYS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | LIPA, LIPC, CETP | TDP1 4612/4885CHRM1 4796/4885AKR1A1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.